AU2019393754A1 - IRE1 small molecule inhibitors - Google Patents
IRE1 small molecule inhibitors Download PDFInfo
- Publication number
- AU2019393754A1 AU2019393754A1 AU2019393754A AU2019393754A AU2019393754A1 AU 2019393754 A1 AU2019393754 A1 AU 2019393754A1 AU 2019393754 A AU2019393754 A AU 2019393754A AU 2019393754 A AU2019393754 A AU 2019393754A AU 2019393754 A1 AU2019393754 A1 AU 2019393754A1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- compound
- c4alkyl
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774794P | 2018-12-03 | 2018-12-03 | |
| US62/774,794 | 2018-12-03 | ||
| PCT/US2019/063921 WO2020117635A1 (en) | 2018-12-03 | 2019-12-02 | Ire1 small molecule inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019393754A1 true AU2019393754A1 (en) | 2021-07-22 |
Family
ID=69024615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019393754A Abandoned AU2019393754A1 (en) | 2018-12-03 | 2019-12-02 | IRE1 small molecule inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12071426B2 (enExample) |
| EP (1) | EP3891137B1 (enExample) |
| JP (1) | JP7546299B2 (enExample) |
| AU (1) | AU2019393754A1 (enExample) |
| CA (1) | CA3121755A1 (enExample) |
| IL (1) | IL283433A (enExample) |
| SG (1) | SG11202105690TA (enExample) |
| WO (1) | WO2020117635A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| SG11202105690TA (en) | 2018-12-03 | 2021-06-29 | Univ Cornell | Ire1 small molecule inhibitors |
| EP3941919B1 (en) | 2019-01-03 | 2025-12-24 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| CN113795307A (zh) * | 2019-02-18 | 2021-12-14 | 基因泰克公司 | 吡啶并嘧啶基化合物及其使用方法 |
| WO2020232403A1 (en) * | 2019-05-15 | 2020-11-19 | Cornell University | Treatment of fibrosis with ire1 small molecule inhibitors |
| EP3983400B1 (en) * | 2019-06-11 | 2025-05-28 | Genentech, Inc. | Quinazolinyl compounds and methods of use |
| US11840523B2 (en) * | 2020-11-13 | 2023-12-12 | The Regents Of The University Of California | IRE1α inhibitors and uses thereof |
| AU2021381949A1 (en) | 2020-11-18 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8664230B2 (en) * | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
| WO2018102751A1 (en) * | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| CN108239074B (zh) | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
| TW201838981A (zh) * | 2017-03-17 | 2018-11-01 | 美商建南德克公司 | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 |
| US20180346446A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| CN111566089B (zh) | 2017-11-10 | 2023-11-17 | 康奈尔大学 | Ire1小分子抑制剂 |
| SG11202105690TA (en) | 2018-12-03 | 2021-06-29 | Univ Cornell | Ire1 small molecule inhibitors |
-
2019
- 2019-12-02 SG SG11202105690TA patent/SG11202105690TA/en unknown
- 2019-12-02 CA CA3121755A patent/CA3121755A1/en not_active Abandoned
- 2019-12-02 JP JP2021531523A patent/JP7546299B2/ja active Active
- 2019-12-02 WO PCT/US2019/063921 patent/WO2020117635A1/en not_active Ceased
- 2019-12-02 US US17/299,684 patent/US12071426B2/en active Active
- 2019-12-02 AU AU2019393754A patent/AU2019393754A1/en not_active Abandoned
- 2019-12-02 EP EP19828388.9A patent/EP3891137B1/en active Active
-
2021
- 2021-05-25 IL IL283433A patent/IL283433A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202105690TA (en) | 2021-06-29 |
| EP3891137A1 (en) | 2021-10-13 |
| US20220356168A1 (en) | 2022-11-10 |
| WO2020117635A1 (en) | 2020-06-11 |
| US12071426B2 (en) | 2024-08-27 |
| IL283433A (en) | 2021-07-29 |
| JP2022511477A (ja) | 2022-01-31 |
| EP3891137B1 (en) | 2024-10-09 |
| JP7546299B2 (ja) | 2024-09-06 |
| CA3121755A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12071426B2 (en) | IRE1 small molecule inhibitors | |
| US11337970B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
| US20230271935A1 (en) | Ire1 small molecule inhibitors | |
| US20210284628A1 (en) | Ire1 small molecule inhibitors | |
| WO2018102751A1 (en) | Ire1 small molecule inhibitors | |
| WO2015006520A1 (en) | Ido inhibitors | |
| JP6916185B2 (ja) | Ｂｔｋ阻害剤としてのイソキノロン類 | |
| WO2018222917A1 (en) | Ire1 small molecule inhibitors | |
| WO2017096045A1 (en) | Multivalent ras binding compounds | |
| CA3150465A1 (en) | Fused ring heteroaryl compounds as ripk1 inhibitors | |
| CN114149424A (zh) | 用于治疗疾病的杂环化合物 | |
| EP4201924B1 (en) | Ire1 small molecule inhibitors | |
| US12479818B2 (en) | Treatment of fibrosis with IRE1 small molecule inhibitors | |
| KR20250164848A (ko) | Kcc2 강화제 및 이의 용도 | |
| WO2015181394A1 (en) | Novel il-2/il-15 receptor antagonist compounds and uses thereof for the treatment of autoimmune and inflammatory diseases or graft rejection | |
| HK40070316A (en) | Heterocyclic compounds for the treatment of disease | |
| JP2025530975A (ja) | Ｉｒａｋ３結合剤としての置換イミダゾピラジン化合物 | |
| HK1260375A1 (en) | Heterocyclic compounds for the treatment of disease | |
| BR122021024771B1 (pt) | Uso de uma combinação de inibidores de jak1/2e pi3ksigma no tratamento de mielofibrose | |
| BR112016023322B1 (pt) | Uso de uma combinação de inibidores de jak e pi3ksigma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |